TBG DIAGNOSTICS LIMITED - Announcements

0.00%

27.0¢

Currently unlisted.

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology... TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.More

Announcements

Filter Results

All Price Sensitive Only

TDL	Removal from Official List - Annual Listing Fees		30/08/21	428.7KB	Share
TDL	Suspension from Official Quotation - Annual Listing Fees	PRICE SENSITIVE	23/08/21	438.25KB	Share
TDL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	03/08/21	1.21MB	Share
TDL	Results of Meeting		29/07/21	221.79KB	Share
TDL	Restatement of FY2020 Financial Statements	PRICE SENSITIVE	29/07/21	110.99KB	Share
TDL	Annual General Meeting Letter to Shareholders		25/06/21	106.52KB	Share
TDL	Notice of Annual General Meeting/Proxy Form		25/06/21	462.57KB	Share
TDL	Corporate Restructure and Sale of TBG Inc. Shares Update		07/06/21	158.17KB	Share
TDL	Annual General Meeting		20/05/21	111.6KB	Share
TDL	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	03/05/21	339.47KB	Share
TDL	Appendix 4G		31/03/21	253.09KB	Share
TDL	Annual Report to shareholders		31/03/21	1.72MB	Share
TDL	Full Year Statutory Accounts		31/03/21	1.33MB	Share
TDL	Initial Director's Interest Notice		24/03/21	145.44KB	Share
TDL	Final Director's Interest Notice		24/03/21	151.92KB	Share
TDL	Director Appointment / Resignation		23/03/21	46.6KB	Share
TDL	ASIC's Determination under s713(6) of the Corporations Act		18/03/21	116.07KB	Share
TDL	Response to ASX Query Letter	PRICE SENSITIVE	03/03/21	1.6MB	Share
TDL	Preliminary Final Report	PRICE SENSITIVE	26/02/21	558.29KB	Share
TDL	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	01/02/21	1.07MB	Share
TDL	Securities Trading Policy		20/11/20	293.01KB	Share
TDL	CE Mark Approval of SARS-CoV-2 Antigen Rapid Test	PRICE SENSITIVE	11/11/20	89.64KB	Share
TDL	Quarterly Activities Report	PRICE SENSITIVE	02/11/20	163.76KB	Share
TDL	Appendix 4C - quarterly	PRICE SENSITIVE	02/11/20	213.8KB	Share
TDL	Distribution Agreement with Medigen Biotechnology Corp	PRICE SENSITIVE	21/09/20	128.89KB	Share
TDL	US FDA Authorisation of COVID-19 Antibody Rapid Test Kits	PRICE SENSITIVE	02/09/20	161.23KB	Share
TDL	Half Yearly Report and Accounts	PRICE SENSITIVE	31/08/20	689.55KB	Share
TDL	Quarterly Activities Report	PRICE SENSITIVE	31/07/20	115.23KB	Share
TDL	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/20	929.79KB	Share
TDL	Results of Meeting		31/07/20	139.58KB	Share
TDL	Taiwan EUA for COVID-19 Nucleic Acid Test Kits	PRICE SENSITIVE	29/07/20	112.95KB	Share
TDL	Notice of Annual General Meeting/Proxy Form		26/06/20	439.59KB	Share
TDL	Appendix 4G		15/06/20	343.41KB	Share
TDL	Annual Report to shareholders		15/06/20	2.03MB	Share
TDL	Full Year Statutory Accounts		12/06/20	1.64MB	Share
TDL	TBG Receives US FDA EUA for COVID-19 Nucleic Acid Test Kits	PRICE SENSITIVE	12/06/20	107.43KB	Share
TDL	Annual General Meeting		11/06/20	61.69KB	Share
TDL	CE Mark approval of COVID-19 Test Kits	PRICE SENSITIVE	21/05/20	105.25KB	Share
TDL	Update on TBG Xiamen COVID-19 Virus Diagnostic Test Kit	PRICE SENSITIVE	05/05/20	101.93KB	Share
TDL	Response to ASX Query Letter	PRICE SENSITIVE	15/04/20	775.22KB	Share
TDL	Update on TBG Xiamen COVID-19 Virus Diagnostic Test Kit	PRICE SENSITIVE	06/04/20	77.16KB	Share
TDL	Suspension from Official Quotation	PRICE SENSITIVE	19/03/20	71.65KB	Share
TDL	Response to ASX Aware Query	PRICE SENSITIVE	19/03/20	210.51KB	Share
TDL	Response to ASX Price Query	PRICE SENSITIVE	18/03/20	195.06KB	Share
TDL	CE Mark approval of COVID-19 Virus Diagnostic Kit		18/03/20	59.1KB	Share
TDL	Trading Halt	PRICE SENSITIVE	17/03/20	116.24KB	Share
TDL	Pause in Trading	PRICE SENSITIVE	17/03/20	116.26KB	Share
TDL	Preliminary Final Report	PRICE SENSITIVE	28/02/20	624.85KB	Share
TDL	ZhangYe approved as designated testing lab for Coronavirus		27/02/20	71.28KB	Share
TDL	Half Yearly Report and Accounts	PRICE SENSITIVE	30/08/19	670.54KB	Share
TDL	Final Director's Interest Notice		28/05/19	168.71KB	Share
TDL	Board Changes		28/05/19	104.65KB	Share
TDL	Results of Meeting		28/05/19	132KB	Share
TDL	Acquisition of Zhangsha ZhangYe Medical Laboratory Complete		03/05/19	227.5KB	Share
TDL	Settlement of Deferred Payment for the Sale of PG500 Assets	PRICE SENSITIVE	03/05/19	227.17KB	Share
TDL	Notice of Annual General Meeting/Proxy Form		26/04/19	977.05KB	Share
TDL	Appendix 4G		27/03/19	214.07KB	Share
TDL	Annual Report to Shareholders		26/03/19	3.01MB	Share
TDL	Full Year Statutory Accounts		21/03/19	1.85MB	Share
TDL	Preliminary Final Report	PRICE SENSITIVE	28/02/19	359.44KB	Share
TDL	COO Appointment/Resignation		01/02/19	105.58KB	Share
TDL	Acquisition of Zhangsha ZhangYe Medical Laboratory Corp	PRICE SENSITIVE	17/12/18	310.52KB	Share
TDL	Half Yearly Report and Accounts	PRICE SENSITIVE	30/08/18	1.05MB	Share
TDL	Initial Director's Interest Notice		30/05/18	387.07KB	Share
TDL	Final Director's Interest Notice		30/05/18	340.44KB	Share
TDL	Results of Meeting		28/05/18	302.11KB	Share
TDL	Company presentation		28/05/18	2.95MB	Share
TDL	Notice of Annual General Meeting/Proxy Form		26/04/18	1.08MB	Share
TDL	Director Appointment/Resignation		26/04/18	62.36KB	Share
TDL	Appendix 4G		23/03/18	255.14KB	Share
TDL	Annual Report to shareholders		22/03/18	3.52MB	Share
TDL	Preliminary Final Report	PRICE SENSITIVE	28/02/18	1.09MB	Share
TDL	Appendix 3B		06/02/18	151.57KB	Share
TDL	Release of Shares from Escrow		17/01/18	54.24KB	Share
TDL	JV with China SOE to meet clinical diagnostic needs	PRICE SENSITIVE	04/12/17	73.77KB	Share
TDL	Market Update	PRICE SENSITIVE	23/10/17	70.44KB	Share
TDL	Change of registry address notification		18/10/17	197.75KB	Share
TDL	Half Yearly Report and Accounts	PRICE SENSITIVE	28/08/17	817.36KB	Share
TDL	ExProbe receives CE Mark and Taiwan FDA approval	PRICE SENSITIVE	24/07/17	75.65KB	Share
TDL	ASHI accreditation for Xiamen facility	PRICE SENSITIVE	19/05/17	72.58KB	Share
TDL	Results of Meeting		12/05/17	74.38KB	Share
TDL	Notice of Annual General Meeting/Proxy Form		11/04/17	646.16KB	Share
TDL	Annual Report to shareholders		21/03/17	1.2MB	Share
TDL	Corporate Governance Statement & Appendix 4G		21/03/17	659.27KB	Share
TDL	Exclusive Licensing Agreement	PRICE SENSITIVE	13/03/17	71.43KB	Share
TDL	Preliminary Final Report	PRICE SENSITIVE	28/02/17	1.73MB	Share
TDL	Receipt of R&D Tax Incentive Refund	PRICE SENSITIVE	02/02/17	188.13KB	Share
TDL	Company Secretary Appointment/Resignation		01/12/16	68.68KB	Share
TDL	AGM 2016 - Results of Meeting		25/11/16	82.26KB	Share
TDL	2016 AGM Presentation	PRICE SENSITIVE	25/11/16	1.49MB	Share
TDL	TBG and Omixon formalise Asia Pacific partnership	PRICE SENSITIVE	15/11/16	37.22KB	Share
TDL	Change in Financial Year End		10/11/16	144.07KB	Share
TDL	Notice of Annual General Meeting/Proxy Form-TDL.AX		21/10/16	478.01KB	Share
TDL	Change of Principal Place of Business Address-TDL.AX		13/10/16	68.12KB	Share
TDL	Corporate Governance Statement & Appendix 4G-TDL.AX		28/09/16	261.06KB	Share
TDL	Annual Report to Shareholders-TDL.AX		28/09/16	1.23MB	Share
TDL	Financial Report for the Year Ended 30 June 2016-TDL.AX		22/09/16	1.53MB	Share
TDL	Preliminary Final Report (Amended)-TDL.AX	PRICE SENSITIVE	31/08/16	835.48KB	Share
TDL	Preliminary Final Report-TDL.AX	PRICE SENSITIVE	31/08/16	938.33KB	Share
TDL	TBG Diagnostics completes strategic review-TDL.AX	PRICE SENSITIVE	22/08/16	29.26KB	Share

TDL Removal from Official List - Annual Listing Fees
30/08/21		428.7KB	Share
TDL Suspension from Official Quotation - Annual Listing Fees
23/08/21	PRICE SENSITIVE	438.25KB	Share
TDL Quarterly Activities/Appendix 4C Cash Flow Report
03/08/21	PRICE SENSITIVE	1.21MB	Share
TDL Results of Meeting
29/07/21		221.79KB	Share
TDL Restatement of FY2020 Financial Statements
29/07/21	PRICE SENSITIVE	110.99KB	Share
TDL Annual General Meeting Letter to Shareholders
25/06/21		106.52KB	Share
TDL Notice of Annual General Meeting/Proxy Form
25/06/21		462.57KB	Share
TDL Corporate Restructure and Sale of TBG Inc. Shares Update
07/06/21		158.17KB	Share
TDL Annual General Meeting
20/05/21		111.6KB	Share
TDL Quarterly Activities Report and Appendix 4C
03/05/21	PRICE SENSITIVE	339.47KB	Share
TDL Appendix 4G
31/03/21		253.09KB	Share
TDL Annual Report to shareholders
31/03/21		1.72MB	Share
TDL Full Year Statutory Accounts
31/03/21		1.33MB	Share
TDL Initial Director's Interest Notice
24/03/21		145.44KB	Share
TDL Final Director's Interest Notice
24/03/21		151.92KB	Share
TDL Director Appointment / Resignation
23/03/21		46.6KB	Share
TDL ASIC's Determination under s713(6) of the Corporations Act
18/03/21		116.07KB	Share
TDL Response to ASX Query Letter
03/03/21	PRICE SENSITIVE	1.6MB	Share
TDL Preliminary Final Report
26/02/21	PRICE SENSITIVE	558.29KB	Share
TDL Quarterly Activities Report and Appendix 4C
01/02/21	PRICE SENSITIVE	1.07MB	Share
TDL Securities Trading Policy
20/11/20		293.01KB	Share
TDL CE Mark Approval of SARS-CoV-2 Antigen Rapid Test
11/11/20	PRICE SENSITIVE	89.64KB	Share
TDL Quarterly Activities Report
02/11/20	PRICE SENSITIVE	163.76KB	Share
TDL Appendix 4C - quarterly
02/11/20	PRICE SENSITIVE	213.8KB	Share
TDL Distribution Agreement with Medigen Biotechnology Corp
21/09/20	PRICE SENSITIVE	128.89KB	Share
TDL US FDA Authorisation of COVID-19 Antibody Rapid Test Kits
02/09/20	PRICE SENSITIVE	161.23KB	Share
TDL Half Yearly Report and Accounts
31/08/20	PRICE SENSITIVE	689.55KB	Share
TDL Quarterly Activities Report
31/07/20	PRICE SENSITIVE	115.23KB	Share
TDL Appendix 4C - quarterly
31/07/20	PRICE SENSITIVE	929.79KB	Share
TDL Results of Meeting
31/07/20		139.58KB	Share
TDL Taiwan EUA for COVID-19 Nucleic Acid Test Kits
29/07/20	PRICE SENSITIVE	112.95KB	Share
TDL Notice of Annual General Meeting/Proxy Form
26/06/20		439.59KB	Share
TDL Appendix 4G
15/06/20		343.41KB	Share
TDL Annual Report to shareholders
15/06/20		2.03MB	Share
TDL Full Year Statutory Accounts
12/06/20		1.64MB	Share
TDL TBG Receives US FDA EUA for COVID-19 Nucleic Acid Test Kits
12/06/20	PRICE SENSITIVE	107.43KB	Share
TDL Annual General Meeting
11/06/20		61.69KB	Share
TDL CE Mark approval of COVID-19 Test Kits
21/05/20	PRICE SENSITIVE	105.25KB	Share
TDL Update on TBG Xiamen COVID-19 Virus Diagnostic Test Kit
05/05/20	PRICE SENSITIVE	101.93KB	Share
TDL Response to ASX Query Letter
15/04/20	PRICE SENSITIVE	775.22KB	Share
TDL Update on TBG Xiamen COVID-19 Virus Diagnostic Test Kit
06/04/20	PRICE SENSITIVE	77.16KB	Share
TDL Suspension from Official Quotation
19/03/20	PRICE SENSITIVE	71.65KB	Share
TDL Response to ASX Aware Query
19/03/20	PRICE SENSITIVE	210.51KB	Share
TDL Response to ASX Price Query
18/03/20	PRICE SENSITIVE	195.06KB	Share
TDL CE Mark approval of COVID-19 Virus Diagnostic Kit
18/03/20		59.1KB	Share
TDL Trading Halt
17/03/20	PRICE SENSITIVE	116.24KB	Share
TDL Pause in Trading
17/03/20	PRICE SENSITIVE	116.26KB	Share
TDL Preliminary Final Report
28/02/20	PRICE SENSITIVE	624.85KB	Share
TDL ZhangYe approved as designated testing lab for Coronavirus
27/02/20		71.28KB	Share
TDL Half Yearly Report and Accounts
30/08/19	PRICE SENSITIVE	670.54KB	Share
TDL Final Director's Interest Notice
28/05/19		168.71KB	Share
TDL Board Changes
28/05/19		104.65KB	Share
TDL Results of Meeting
28/05/19		132KB	Share
TDL Acquisition of Zhangsha ZhangYe Medical Laboratory Complete
03/05/19		227.5KB	Share
TDL Settlement of Deferred Payment for the Sale of PG500 Assets
03/05/19	PRICE SENSITIVE	227.17KB	Share
TDL Notice of Annual General Meeting/Proxy Form
26/04/19		977.05KB	Share
TDL Appendix 4G
27/03/19		214.07KB	Share
TDL Annual Report to Shareholders
26/03/19		3.01MB	Share
TDL Full Year Statutory Accounts
21/03/19		1.85MB	Share
TDL Preliminary Final Report
28/02/19	PRICE SENSITIVE	359.44KB	Share
TDL COO Appointment/Resignation
01/02/19		105.58KB	Share
TDL Acquisition of Zhangsha ZhangYe Medical Laboratory Corp
17/12/18	PRICE SENSITIVE	310.52KB	Share
TDL Half Yearly Report and Accounts
30/08/18	PRICE SENSITIVE	1.05MB	Share
TDL Initial Director's Interest Notice
30/05/18		387.07KB	Share
TDL Final Director's Interest Notice
30/05/18		340.44KB	Share
TDL Results of Meeting
28/05/18		302.11KB	Share
TDL Company presentation
28/05/18		2.95MB	Share
TDL Notice of Annual General Meeting/Proxy Form
26/04/18		1.08MB	Share
TDL Director Appointment/Resignation
26/04/18		62.36KB	Share
TDL Appendix 4G
23/03/18		255.14KB	Share
TDL Annual Report to shareholders
22/03/18		3.52MB	Share
TDL Preliminary Final Report
28/02/18	PRICE SENSITIVE	1.09MB	Share
TDL Appendix 3B
06/02/18		151.57KB	Share
TDL Release of Shares from Escrow
17/01/18		54.24KB	Share
TDL JV with China SOE to meet clinical diagnostic needs
04/12/17	PRICE SENSITIVE	73.77KB	Share
TDL Market Update
23/10/17	PRICE SENSITIVE	70.44KB	Share
TDL Change of registry address notification
18/10/17		197.75KB	Share
TDL Half Yearly Report and Accounts
28/08/17	PRICE SENSITIVE	817.36KB	Share
TDL ExProbe receives CE Mark and Taiwan FDA approval
24/07/17	PRICE SENSITIVE	75.65KB	Share
TDL ASHI accreditation for Xiamen facility
19/05/17	PRICE SENSITIVE	72.58KB	Share
TDL Results of Meeting
12/05/17		74.38KB	Share
TDL Notice of Annual General Meeting/Proxy Form
11/04/17		646.16KB	Share
TDL Annual Report to shareholders
21/03/17		1.2MB	Share
TDL Corporate Governance Statement & Appendix 4G
21/03/17		659.27KB	Share
TDL Exclusive Licensing Agreement
13/03/17	PRICE SENSITIVE	71.43KB	Share
TDL Preliminary Final Report
28/02/17	PRICE SENSITIVE	1.73MB	Share
TDL Receipt of R&D Tax Incentive Refund
02/02/17	PRICE SENSITIVE	188.13KB	Share
TDL Company Secretary Appointment/Resignation
01/12/16		68.68KB	Share
TDL AGM 2016 - Results of Meeting
25/11/16		82.26KB	Share
TDL 2016 AGM Presentation
25/11/16	PRICE SENSITIVE	1.49MB	Share
TDL TBG and Omixon formalise Asia Pacific partnership
15/11/16	PRICE SENSITIVE	37.22KB	Share
TDL Change in Financial Year End
10/11/16		144.07KB	Share
TDL Notice of Annual General Meeting/Proxy Form-TDL.AX
21/10/16		478.01KB	Share
TDL Change of Principal Place of Business Address-TDL.AX
13/10/16		68.12KB	Share
TDL Corporate Governance Statement & Appendix 4G-TDL.AX
28/09/16		261.06KB	Share
TDL Annual Report to Shareholders-TDL.AX
28/09/16		1.23MB	Share
TDL Financial Report for the Year Ended 30 June 2016-TDL.AX
22/09/16		1.53MB	Share
TDL Preliminary Final Report (Amended)-TDL.AX
31/08/16	PRICE SENSITIVE	835.48KB	Share
TDL Preliminary Final Report-TDL.AX
31/08/16	PRICE SENSITIVE	938.33KB	Share
TDL TBG Diagnostics completes strategic review-TDL.AX
22/08/16	PRICE SENSITIVE	29.26KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

TBG DIAGNOSTICS LIMITED - Announcements

Announcements

Top Stories